Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice

Behavioural Brain Research

Volumn 228, Issue 2, 2012, Pages 406-414

  Catches, Justin S ^a   Xu, Jian ^a   Contractor, Anis ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anxiety; Depression; GluK4; Hippocampus; Kainate receptor; Mossy fiber

Indexed keywords

KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; FOOD PREFERENCE; FORCED SWIMMING TEST; GENE; GENETIC VARIABILITY; GRIK4 GENE; HETEROZYGOSITY; HIGH RISK BEHAVIOR; HIPPOCAMPAL MOSSY FIBER; LOCOMOTION; LONG TERM POTENTIATION; MAZE TEST; MOOD DISORDER; MOTOR DYSFUNCTION; MOUSE; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; EXPLORATORY BEHAVIOR; FOOD PREFERENCES; HIPPOCAMPUS; LONG-TERM POTENTIATION; MAZE LEARNING; MICE; MICE, KNOCKOUT; MOSSY FIBERS, HIPPOCAMPAL; MOTOR ACTIVITY; PATCH-CLAMP TECHNIQUES; RECEPTORS, KAINIC ACID; SUCROSE; SWEETENING AGENTS; SWIMMING;

EID: 84856230496     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.12.026     Document Type: Article

References (60)

1. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
2. Duman R.S., Li N., Liu R-J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
3. Altamura C.A., Mauri M.C., Ferrara A., Moro A.R., D'Andrea G., Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993, 150:1731-1733.
4. Kim J.S., Schmid-Burgk W., Claus D., Kornhuber H.H. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982, 232:299-304.
5. Mauri M.C., Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998, 37:124-129.
6. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1155-1158.
7. Ajilore O., Haroon E., Kumaran S., Darwin C., Binesh N., Mintz J., et al. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology 2007, 32:1224-1231.
8. Taylor M.J., Mannie Z.N., Norbury R., Near J., Cowen P.J. Elevated cortical glutamate in young people at increased familial risk of depression. Int J Neuropsychopharmacol 2011, 14:255-259.
9. Auer D.P., Pütz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000, 47:305-313.
10. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and {gamma}-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007, 64:193-200.
11. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y-T., Appel M., Rothman D.L., et al. Subtype-specific alterations of {gamma}-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713.
12. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011, 224:107-111.
13. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P-f, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
14. Wang J., Goffer Y., Xu D., Tukey D.S., Shamir D.B., Eberle S.E., et al. A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology 2011, 115:812-821.
15. Quan M.N., Zhang N., Wang Y.Y., Zhang T., Yang Z. Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience 2011, 182:88-97.
16. Li N., Lee B., Liu R-J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
17. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
18. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A Randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
19. Jane D.E., Lodge D., Collingridge G.L. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology 2009, 56:90-113.
20. Matute C. Therapeutic potential of kainate receptors. CNS Neurosci Ther 2011, 17:661-669.
21. Contractor A., Mulle C., Swanson G.T. Kainate receptors coming of age: milestones of two decades of research. Trends Neurosci 2011, 34:154-163.
22. Fernandes H., Catches J., Petralia R., Copits B., Xu J., Russell T., et al. High-affinity kainate receptor subunits are necessary for ionotropic but not metabotropic signaling. Neuron 2009, 63:818-829.
23. Werner P., Voigt M., Keinanen K., Wisden W., Seeburg P.H. Cloning of a putative high-affinity kainate receptor expressed predominantly in hippocampal CA3 cells. Nature 1991, 351:742-744.
24. Wisden W., Seeburg P.H. A complex mosaic of high-affinity kainate receptors in rat brain. J Neurosci 1993, 13:3582-3598.
25. Bahn S., Volk B., Wisden W. Kainate receptor gene expression in the developing rat brain. J Neurosci 1994, 14:5525-5547.
26. Pinheiro P.S., Perrais D., Coussen F., Barhanin J., Bettler B., Mann J.R., et al. GluR7 is an essential subunit of presynaptic kainate autoreceptors at hippocampal mossy fiber synapses. Proc Natl Acad Sci USA 2007, 104:12181-12186.
27. Schmitz D., Mellor J., Nicoll R.A. Presynaptic kainate receptor mediation of frequency facilitation at hippocampal mossy fiber synapses. Science 2001, 291:1972-1976.
28. Fisahn A., Contractor A., Traub R.D., Buhl E.H., Heinemann S.F., McBain C.J. Distinct roles for the kainate receptor subunits GluR5 and GluR6 in kainate-induced hippocampal gamma oscillations. J Neurosci 2004, 24:9658-9668.
29. Contractor A., Swanson G., Heinemann S.F. Kainate receptors are involved in short- and long-term plasticity at mossy fiber synapses in the hippocampus. Neuron 2001, 29:209-216.
30. Paddock S., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007, 164:1181-1188.
31. Pickard B.S., Malloy M.P., Christoforou A., Thomson P.A., Evans K.L., Morris S.W., et al. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 2006, 11:847-857.
32. Gejman P.V., Sanders A.R., Kendler K.S. Genetics of schizophrenia: new findings and challenges. Annu Rev Genomics Hum Genet 2011, 12:121-144.
33. Knight H.M., Walker R., James R., Porteous D.J., Muir W.J., Blackwood D.H.R., et al. GRIK4/KA1 protein expression in human brain and correlation with bipolar disorder risk variant status. Am J Med Genet B: Neuropsychiatr Genet 2012, 159B:21-29.
34. Pickard B.S., Knight H.M., Hamilton R.S., Soares D.C., Walker R., Boyd J.K., et al. A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder. Proc Natl Acad Sci USA 2008, 105:14940-14945.
35. Whalley H.C., Pickard B.S., McIntosh A.M., Zuliani R., Johnstone E.C., Blackwood D.H., et al. A GRIK4 variant conferring protection against bipolar disorder modulates hippocampal function. Mol Psychiatry 2009, 14:467-468.
36. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991, 38:63-67.
37. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
38. K6 at hippocampal mossy fiber synapses. J Neurosci 2004, 24:10093-10098.
39. Schmitz D., Mellor J., Breustedt J., Nicoll R.A. Presynaptic kainate receptors impart an associative property to hippocampal mossy fiber long-term potentiation. Nat Neurosci 2003, 6:1058.
40. -/- mice. J Neurosci 2003, 23:422-429.
41. Schmitz D., Frerking M., Nicoll R.A. Synaptic activation of presynaptic kainate receptors on hippocampal mossy fiber synapses. Neuron 2000, 27:327-338.
42. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs Is decreased in frontal cortex of neuroleptic-free schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J Neurochem 1998, 71:2454-2464.
43. Porter R.H., Eastwood S.L., Harrison P.J. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 1997, 751:217-231.
44. Scarr E., Beneyto M., Meador-Woodruff J.H., Dean B. Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 2005, 30:1521-1531.
45. Zarate C.A., Singh J.B., Quiroz J.A., De Jesus G., Denicoff K.K., Luckenbaugh D.A., et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153-155.
46. Li N., Liu R-J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011, 69:754-761.
47. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033.
48. Shaltiel G., Maeng S., Malkesman O., Pearson B., Schloesser R.J., Tragon T., et al. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 2008, 13:858-872.
49. Dick D.M., Foroud T., Flury L., Bowman E.S., Miller M.J., Rau N.L., et al. Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet 2003, 73:107-114.
50. Schulze T.G., Buervenich S., Badner J.A., Steele C.J.M., Detera-Wadleigh S.D., Dick D., et al. Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective disorder in the national institute of mental health genetics initiative pedigrees. Biol Psychiatry 2004, 56:18-23.
51. Shibata H., Joo A., Fujii Y., Tani A., Makino C., Hirata N., et al. Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia. Psychiatr Genet 2001, 11:139-144.
52. Wu L.J., Ko S.W., Toyoda H., Zhao M.G., Xu H., Vadakkan K.I., et al. Increased anxiety-like behavior and enhanced synaptic efficacy in the amygdala of GluR5 knockout mice. PLoS One 2007, 2:e167.
53. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20:9104-9110.
54. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004, 56:570-580.
55. Pham K., Nacher J., Hof P.R., McEwen B.S. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur J Neurosci 2003, 17:879-886.
56. Hanson N.D., Nemeroff C.B., Owens M.J. Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus. J Pharmacol Exp Ther 2011, 337:180-186.
57. Lauri S.E., Bortolotto Z.A., Bleakman D., Ornstein P.L., Lodge D., Isaac J.T., et al. A critical role of a facilitatory presynaptic kainate receptor in mossy fiber LTP. Neuron 2001, 32:697-709.
58. Harris E.W., Cotman C.W. Long-term potentiation of guinea pig mossy fiber responses is not blocked by N-methyl d-aspartate antagonists. Neurosci Lett 1986, 70:132-137.
59. Zalutsky R.A., Nicoll R.A. Comparison of two forms of long-term potentiation in single hippocampal neurons. Science 1990, 248:1619-1624.
60. Kobayashi K., Ikeda Y., Sakai A., Yamasaki N., Haneda E., Miyakawa T., et al. Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci USA 2010, 107:8434-8439.